NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 138 filers reported holding NEVRO CORP in Q3 2023. The put-call ratio across all filers is 2.46 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $601,408 | +7.2% | 31,294 | +41.9% | 0.00% | 0.0% |
| Q2 2023 | $560,789 | -10.9% | 22,059 | +26.7% | 0.00% | 0.0% |
| Q1 2023 | $629,686 | -25.7% | 17,410 | -18.5% | 0.00% | 0.0% |
| Q4 2022 | $847,347 | +28.0% | 21,353 | +50.1% | 0.00% | -33.3% |
| Q3 2022 | $662,000 | +17.8% | 14,226 | +10.9% | 0.00% | 0.0% |
| Q2 2022 | $562,000 | +83.7% | 12,828 | +203.1% | 0.00% | +200.0% |
| Q1 2022 | $306,000 | +12.5% | 4,232 | +26.3% | 0.00% | 0.0% |
| Q4 2021 | $272,000 | -0.4% | 3,352 | +103.8% | 0.00% | 0.0% |
| Q2 2021 | $273,000 | +25.8% | 1,645 | +31.0% | 0.00% | 0.0% |
| Q4 2020 | $217,000 | -36.5% | 1,256 | -77.1% | 0.00% | -50.0% |
| Q1 2019 | $342,000 | -37.0% | 5,479 | -25.5% | 0.00% | -50.0% |
| Q2 2016 | $543,000 | +52.5% | 7,359 | +16.2% | 0.00% | +100.0% |
| Q1 2016 | $356,000 | – | 6,334 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |